- Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women
[作者:Lee, E; McKean-Cowdin, R; Ma, HY; Spicer, DV; Van Den Berg, D; Bernstein, L; Ursin, G,期刊:Journal of clinical oncology, 页码:4373-4380 , 文章类型: Article,,卷期:2011年29-33]
- Purpose Triple-negative breast cancers (TNBCs) are tumors with low or no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. These tumors have a poor prognosis, remain a c...
- Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study
[作者:Ready, NE; Dudek, AZ; Pang, HH; Hodgson, LD; Graziano, SL; Green, MR; Vokes, EE,期刊:Journal of clinical oncology, 页码:4436-4441 , 文章类型: Article,,卷期:2011年29-33]
- Purpose The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients with extensivestage small-cell lung cancer (ES-SCLC). Patients and Methods Patients with ES-SCLC received cisplatin 30 mg/m(2) and ...
- Compromised Health-Related Quality of Life in Patients With Low-Grade Glioma
[作者:Aaronson, NK; Taphoorn, MJB; Heimans, JJ; Postma, TJ; Gundy, CM; Beute, GN; Slotman, BJ; Klein, M,期刊:Journal of clinical oncology, 页码:4430-4435 , 文章类型: Article,,卷期:2011年29-33]
- Purpose To investigate the generic and condition-specific health-related quality of life (HRQL) of patients with low-grade glioma (LGG). Patients and Methods A total of 195 patients with LGG, which was diagnosed, on aver...
- Discordance in Perceived Needs Between Patients and Physicians in Oncology Practice: A Nationwide Survey in Korea
[作者:Shin, DW; Kim, SY; Cho, J; Sanson-Fisher, RW; Guallar, E; Chai, GY; Kim, HS; Park, BR; Park, EC; Park, JH,期刊:Journal of clinical oncology, 页码:4424-4429 , 文章类型: Article,,卷期:2011年29-33]
- Purpose Identification of supportive care needs in patients with cancer is essential for planning appropriate interventions. We aimed to determine patient-physician concordance in perceived supportive care needs in cance...
- Phase II Trial of Preoperative Chemoradiotherapy Followed by Surgical Resection in Patients With Superior Sulcus Non-Small-Cell Lung Cancers: Report of Japan Clinical Oncology Group Trial 9806 (vol 26, pg 644, 2008)
[作者:Kunitoh, H; Kato, H; Tsuboi, M; Ichinose, Y,期刊:Journal of clinical oncology, 页码:4472-4472 , 文章类型: Correction,,卷期:2011年29-33]
-
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
[作者:Park, JR; Scott, JR; Stewart, CF; London, WB; Naranjo, A; Santana, VM; Shaw, PJ; Cohn, SL; Matthay, KK,期刊:Journal of clinical oncology, 页码:4351-4357 , 文章类型: Article,,卷期:2011年29-33]
- Purpose To assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB). Patients and Methods Enrolled patients received two cycle...
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
[作者:Sasako, M; Sakuramoto, S; Katai, H; Kinoshita, T; Furukawa, H; Yamaguchi, T; Nashimoto, A; Fujii, M; Nakajima, T; Ohashi, Y,期刊:Journal of clinical oncology, 页码:4387-4393 , 文章类型: Article,,卷期:2011年29-33]
- Purpose The first planned interim analysis (median follow-up, 3 years) of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine derivative S-1 significantly improved overall s...
- Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
[作者:Walter, RB; Othus, M; Borthakur, G; Ravandi, F; Cortes, JE; Pierce, SA; Appelbaum, FR; Kantarjian, HA; Estey, EH,期刊:Journal of clinical oncology, 页码:4417-4423 , 文章类型: Article,,卷期:2011年29-33]
- Purpose Outcome in acute myeloid leukemia (AML) worsens with age, at least in part because of higher treatment-related mortality (TRM) in older patients. Eligibility for intensive AML treatment protocols is therefore typ...
|